LEGN — Legend Biotech Corporation

Legend Biotech Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Trade Sales: Approximately $597 million for CARVYKTI, up 52% year-over-year, with 36% growth in the U.S. and over 200% growth internationally.
• Total Revenue: $305 million, including collaboration revenue of $298 million.
• Gross Margin: 41%, down from 57% in Q4 2025, primarily due to one-time manufacturing ramp-up costs.
• Adjusted Net Loss: $11 million, improving from a loss of $27 million in Q1 2025. Expected to achieve profitability on an adjusted basis in 2026.
• Cash Position: Approximately $835 million in cash, cash equivalents, and time deposits, with no long-term debt.

2. Strategic Updates and Business Highlights

• Commercial Performance: Continued strong demand for CARVYKTI, with significant growth in earlier treatment lines. Nearly 80% of patients treated in community settings.
• Pipeline Development: Advancements in CARVYKTI trials (CARTITUDE-5 and CARTITUDE-6) and new In Vivo CAR-T programs targeting BCMA and GPRC5D, with initial data expected later in 2026.
• Scientific Advisory Board: Engaged six experts to enhance R&D strategy and pipeline development.

3. Forward Guidance and Outlook

• Profitability: Confident in achieving company-wide profitability on an adjusted basis in 2026, with expectations for gross margins to recover to over 50% in Q2.
• Growth Trajectory: Anticipate continued sequential growth in CARVYKTI sales throughout 2026, supported by expanding market penetration and community adoption.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The significant drop in gross margin due to one-time costs raises concerns about ongoing profitability metrics.
• Competition: Potential impact from the approval of TECVAYLI in the second line of treatment and other bispecific therapies, although management believes the market remains underserved.
• Event-Driven Trials: The timing for data from pivotal trials (CARTITUDE-5 and CARTITUDE-6) remains uncertain, which could affect investor sentiment and stock performance.

5. Notable Q&A Insights

• In Vivo CAR-T Programs: Management confirmed that the upcoming In Vivo CD19/CD20 program (LB2501) is distinct from other platforms and is expected to show promising safety and efficacy data, although specifics are pending.
• Community Adoption: Positive feedback from community oncology centers regarding CARVYKTI administration, with plans to onboard more centers.
• Trial Comparisons: Management expressed confidence in CARVYKTI's performance against existing therapies, particularly in the context of the CARTITUDE-5 trial, which targets patients not eligible for stem cell transplants.
• Cost Structure: Adjustments in financial reporting were clarified, indicating that certain non-cash items will continue to affect the adjusted net income metric.

Overall, Legend Biotech demonstrated strong commercial growth in Q1 2026, with a focus on expanding its CARVYKTI market presence and advancing its innovative pipeline, while also facing challenges related to competition and margin pressures.